Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT.

Literature DB >> 14985862

Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT.

Alexander Matthies¹, Samer Ezziddin, Eva-Maria Ulrich, Holger Palmedo, Hans-Jürgen Biersack, Hans Bender, Stefan Guhlke.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2004 PMID： 14985862 DOI： 10.1007/s00259-003-1437-1

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

2 in total

1. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Authors: Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch
Journal: J Nucl Med Date: 2003-04 Impact factor: 10.057

2. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.

Authors: E Fricke; S Machtens; M Hofmann; J van den Hoff; S Bergh; T Brunkhorst; G J Meyer; J H Karstens; W H Knapp; A R Boerner
Journal: Eur J Nucl Med Mol Imaging Date: 2003-02-13 Impact factor: 9.236

2 in total

16 in total

Review 1. GCPII imaging and cancer.

Authors: C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal: Curr Med Chem Date: 2012 Impact factor: 4.530

Review 2. Molecular imaging of prostate cancer: PET radiotracers.

Authors: Hossein Jadvar
Journal: AJR Am J Roentgenol Date: 2012-08 Impact factor: 3.959

3. Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy.

Authors: J Amanie; H S Jans; M Wuest; N Pervez; A Murtha; N Usmani; D Yee; R Pearcey; B Danielson; S Patel; R Macewan; C Field; D Robinson; J Wilson; D Lewis; M Parliament; A J B McEwan
Journal: Curr Oncol Date: 2013-04 Impact factor: 3.677

Review 4. Imaging and evaluation of patients with high-risk prostate cancer.

Authors: Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal: Nat Rev Urol Date: 2015-10-20 Impact factor: 14.432

Review 5. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

Authors: Giorgia Zadra; Massimo Loda
Journal: Cold Spring Harb Perspect Med Date: 2018-10-01 Impact factor: 6.915

6. [¹⁸F]Fluorocholine and [¹⁸F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM.

Authors: Taylor R Kavanagh; William J Mischler; Eline E Verwer; You Feng; Kazue Takahashi; Shuyan Wang; Timothy M Shoup; Ramesh Neelamegam; Jing Yang; Nicolas J Guehl; Chongzhao Ran; Walter Massefski; Ye Cui; Souheil El-Chemaly; Peter M Sadow; William M Oldham; Marie F Kijewski; Georges El Fakhri; Marc D Normandin; Carmen Priolo
Journal: Clin Cancer Res Date: 2018-07-27 Impact factor: 12.531

Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT.

1. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

2. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.

Review 1. GCPII imaging and cancer.

Review 2. Molecular imaging of prostate cancer: PET radiotracers.

3. Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy.

Review 4. Imaging and evaluation of patients with high-risk prostate cancer.

Review 5. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

6. [¹⁸F]Fluorocholine and [¹⁸F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM.

Review 7. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Review 8. Functional imaging for prostate cancer: therapeutic implications.

9. [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology.

10. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.

Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT.

1. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

2. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.

Review 1. GCPII imaging and cancer.

Review 2. Molecular imaging of prostate cancer: PET radiotracers.

3. Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy.

Review 4. Imaging and evaluation of patients with high-risk prostate cancer.

Review 5. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

6. [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM.

Review 7. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

Review 8. Functional imaging for prostate cancer: therapeutic implications.

9. [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology.

10. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.

6. [¹⁸F]Fluorocholine and [¹⁸F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM.